← EyePoint Pharmaceuticals, Inc. (EYPT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
EyePoint Pharmaceuticals, Inc. (EYPT)
Laboratory Analytical Instruments · market cap $333M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
EyePoint Pharmaceuticals (EYPT) is a Watertown, MA-based ophthalmic drug delivery company leveraging MEMS and nanotechnology platforms, currently trading at ~$13.3 with a $1.115B market cap. Its pipeline spans multiple sustained-release ocular assets across uveitis, wet AMD, and diabetic macular edema, with the FAI insert in Phase 3 for non-infectious uveitis and aflibercept 2.0mg in Phase 3 for wet AMD representing the nearest catalysts. The company faces a critical financial constraint: $77.7M in cash against a stated runway of only ~2.9 months, making near-term capital raises a near-certainty.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-08-15 (est.)Phase 3 · EYP-1901imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Latanoprost ophthalmic solution | Phase 2 | Ocular Hypertension |
| FAI insert | Phase 3 | Non-Infectious Uveitis |
| FAI Insert administered using the Mk II inserter | Phase 3 | Non-Infectious Uveitis |
| EYP-1901 | Phase 3 | Diabetic Macular Edema |
| AKB-9778 | Phase 2 | Nonproliferative Diabetic Retinopathy |
Price & technical context
3-month
-77.5%
6-month
-75.7%
12-month
-74.8%
52-wk range
$3.23–$18.85
vs 50-day MA
-53.7%
vs 200-day MA
-74.1%
Realized vol
132.3%
Max drawdown
-82.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EYPT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.